Philippines BIR Launches Nationwide Raid on Illegal E-Cigarette Sellers

Oct.17.2024
Philippines BIR Launches Nationwide Raid on Illegal E-Cigarette Sellers
Philippine BIR chief orders nationwide crackdown on illegal e-cigarette retailers and distributors, warning of surprise inspections and criminal cases.

According to a report by Journal on October 17th, Romeo D. Lumagui Jr., the Commissioner of the Bureau of Internal Revenue (BIR) in the Philippines, has ordered all tax officials to conduct nationwide raids on illegal e-cigarette retailers and distributors.


Tax office branches and tax district offices across the region have been instructed to monitor and conduct raids on all businesses involved in the illegal sale of e-cigarettes. Authorities emphasize that the main targets of this operation are retailers and distributors, as they are accomplices of e-cigarette smugglers.


Director Lu Maqiu of the BIR emphasized that


Illegal e-cigarette distributors will be subjected to a surprise inspection. They are accomplices to e-cigarette smugglers. Without distributors, there would be no smugglers. Smugglers will be forced to comply with BIR regulations.


The illegal e-cigarette industry has been warned multiple times to follow BIR regulations, but they have repeatedly ignored the law. Therefore, the BIR will intensify its enforcement actions against illegal e-cigarette retailers and distributors. It is anticipated that there will be raids and criminal cases.


The director encouraged the public to report organizations involved in illegal e-cigarette activities to the national tax authority.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global has named James Yamanaka, previously Global Head of Strategy at British American Tobacco (BTI), as its new CEO. His appointment is expected to take effect around January 15, 2026, and he will also join the company’s board. Yamanaka brings more than 20 years of strategic and managerial experience from roles across Europe and Asia at BTI.
Nov.26
Japan Tobacco launches third limited-edition Ploom AURA color “Aqua Green,” rolling out nationwide in December
Japan Tobacco launches third limited-edition Ploom AURA color “Aqua Green,” rolling out nationwide in December
Japan Tobacco (JT) announced that its heated tobacco device Ploom AURA will introduce a new limited-edition “Aqua Green” color in December. As the third release in JT’s 2025 limited series, the model will be available through official channels from December 1 and will roll out to convenience stores and selected tobacco retailers nationwide starting December 9.
Nov.24 by 2FIRSTS.ai
Zyn Retailers to Pay $3M Settlement for Violating San Francisco’s Flavored Nicotine Ban
Zyn Retailers to Pay $3M Settlement for Violating San Francisco’s Flavored Nicotine Ban
San Francisco’s City Attorney’s Office has reached a $3 million settlement with three online tobacco retailers accused of illegally selling flavored Zyn nicotine pouches, violating the city’s 2017 ban on flavored tobacco products.
Oct.29
BAT appoints Matthew Wright as Independent Non-Executive Director, effective November 1, 2025
BAT appoints Matthew Wright as Independent Non-Executive Director, effective November 1, 2025
Matthew Wright appointed as independent non-executive director of British American Tobacco, effective November 1, bringing extensive international executive experience.
Oct.15 by 2FIRSTS.ai
Philip Morris Korea Extends IQOS ILUMA i Warranty to 18 Months, Says Move Will Boost Smoke-Free Product Growth
Philip Morris Korea Extends IQOS ILUMA i Warranty to 18 Months, Says Move Will Boost Smoke-Free Product Growth
Philip Morris International’s Korea unit has extended the warranty for the “IQOS ILUMA i” heated tobacco series from 12 to 18 months, applying it retroactively to existing purchases, aiming to enhance user experience and market competitiveness.
Oct.15 by 2FIRSTS.ai
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21